G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients
- Sponsor
- National Cancer Institute, Naples
- Study ID
- NCT00401609
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 70 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- gemcitabine — DRUG
- vinorelbine — DRUG
- cisplatin — DRUG
- etoposide — DRUG
- carboplatin — DRUG
Study Details
The purpose of this study is to describe the activity and toxicity of gemcitabine combined with four different drugs (carboplatin or cisplatin or etoposide or vinorelbine) as first line treatment of elderly patients with extensive small cell lung cancer.
Key Dates
- Start date
- Nov 30, 2000
- Status verified
- Jan 2016
- Primary completion
- Dec 31, 2007
- Completion
- Feb 28, 2009
Study Design
- Enrollment
- 85 participants
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
to evaluate activity and toxicity of GEMVIN combination
Related Studies
- Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56PHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)Recruiting · Tempus AI · Los Alamitos, California